PARP inhibitor drugs can be ‘tuned’ for better killing of tumor cells

A prospective ‘PARP inhibitor’ drug that has struggled to show effectiveness in clinical trials against cancers can be structurally modified to greatly increase its power to kill tumor cells, researchers from Penn Medicine report this week in Science.